TP53 and head and neck squamous cell carcinoma: Another phase I study (NCT02432963) with 11 patients (one HNSCC) of p53-overexpressing solid cancers (defined as >10% of cells staining positive for p53) demonstrated that the vaccination with p53-expressing MVA (p53MVA), in combination of pembrolizumab, was effective, resulting in clinical benefits in a select few patients [52].